A significant interaction was observed between the GBS-DS and time on serum NfL levels (likelihood-ratio test p < 0.0001), indicating that patients with more severe disease exhibited a sharper increase in serum NfL and subsequently slower normalisation towards baseline serum NfL levels. The gene discussed is NEFL; the disease is Guillain-Barre syndrome.